Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Programmed Death Receptor-1-directed Antibody Interactions [MoA]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

Drug	Reports	Deaths	Death Rate	Hosp.	Life-Threat.	Avg Age	% Female
NIVOLUMAB	87,742	23,086	26.3%	36,530	6,137	64.2 yrs	34.0%
PEMBROLIZUMAB	83,779	15,543	18.6%	35,472	5,406	64.1 yrs	49.9%
ATEZOLIZUMAB	33,703	8,520	25.3%	15,094	1,505	65.3 yrs	39.1%
TISLELIZUMAB	4,996	114	2.3%	2,586	292	62.9 yrs	26.5%
TORIPALIMAB	1,344	65	4.8%	823	135	58.0 yrs	24.9%
DOSTARLIMAB	893	130	14.6%	441	52	65.8 yrs	91.6%
RETIFANLIMAB	96	17	17.7%	89	13	59.5 yrs	63.2%

Head-to-Head Comparisons

NIVOLUMAB vs PEMBROLIZUMAB NIVOLUMAB vs ATEZOLIZUMAB NIVOLUMAB vs TISLELIZUMAB NIVOLUMAB vs TORIPALIMAB PEMBROLIZUMAB vs ATEZOLIZUMAB PEMBROLIZUMAB vs TISLELIZUMAB PEMBROLIZUMAB vs TORIPALIMAB ATEZOLIZUMAB vs TISLELIZUMAB ATEZOLIZUMAB vs TORIPALIMAB TISLELIZUMAB vs TORIPALIMAB

← Back to Programmed Death Receptor-1-directed Antibody Interactions [MoA] Class side effects →